Gougelet A. Exosomal microRNAs as a potential therapeutic strategy in hepatocellular carcinoma. World J Hepatol 2018; 10(11): 785-789 [PMID: 30533178 DOI: 10.4254/wjh.v10.i11.785]
Corresponding Author of This Article
Angélique Gougelet, PhD, Research Scientist, Inserm, U1016, Institut Cochin, 24, rue du Faubourg Saint Jacques, Paris 75014, France. angelique.gougelet@inserm.fr
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Hepatol. Nov 27, 2018; 10(11): 785-789 Published online Nov 27, 2018. doi: 10.4254/wjh.v10.i11.785
Exosomal microRNAs as a potential therapeutic strategy in hepatocellular carcinoma
Angélique Gougelet
Angélique Gougelet, Inserm, U1016, Institut Cochin, Paris 75014, France
Angélique Gougelet, Cnrs, UMR8104, Paris 75014, France
Angélique Gougelet, Université Paris Descartes, Sorbonne Paris Cité, Paris 75006, France
Author contributions: Gougelet A constructed and wrote the manuscript.
Conflict-of-interest statement: The author has no conflict of interest to declare. No financial support.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Angélique Gougelet, PhD, Research Scientist, Inserm, U1016, Institut Cochin, 24, rue du Faubourg Saint Jacques, Paris 75014, France. angelique.gougelet@inserm.fr
Telephone: +33-14-4412446 Fax: +33-14-4412421
Received: August 2, 2018 Peer-review started: August 3, 2018 First decision: August 24, 2018 Revised: September 5, 2018 Accepted: October 10, 2018 Article in press: October 10, 2018 Published online: November 27, 2018
Core Tip
Core tip: Despite the intensive research efforts to identify the molecular events responsible for the emergence of liver cancer, hepatocellular carcinoma (HCC) remains a major health problem worldwide. Thus, the identification of new therapeutic opportunities to counteract the challenging issues linked to HCC heterogeneity and resistance to conventional treatments is a short-term necessity. Over the last few decades, microRNAs have appeared as interesting therapeutic strategies with their pleiotropic inhibitory action, but the use of a delivery system is a requirement for miRNA mimic administration. Exosomes, which are small vesicles naturally produced by immune cells and aberrantly by cancer cells, have recently emerged as a promising vehicle.
